by Katrina Carr | Nov 4, 2019 | Cost & Coping
Durvalumab maintains NSCLC patient-reported outcomes BY WILL PASS Durvalumab provides clinically meaningful improvements in non–small cell lung cancer (NSCLC) without diminishing patient-reported outcomes (PROs), based on data from the phase 3 PACIFIC trial. This...
by Katrina Carr | May 13, 2019 | Cost & Coping
Continued smoking with cancer poses significant economic burden BY CHRISTINE KILGORE MDedge News Continued smoking by patients with cancer increases the risk of cancer treatment failure and leads to more than $10,000 of additional costs per patient, on average, for...
by Katrina Carr | Apr 12, 2019 | Cost & Coping
Financial toxicity high for lung cancer patients By Alicia GallegosMDedge News When making decisions about lung cancer treatment, a patient’s finances frequently affects the care route they choose, said Leah Backhus, MD, chief of thoracic surgery at VA Palo Alto in...
